CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 175 enrolled
Drug / intervention
LBH589drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00621244
NCT00621244Phase 2Completed
CompareCT.gov

A Phase IA/II, Two-arm, Multi-center, Open-label, Dose-escalation Study of LBH589 Administered Orally Via Different Dosing Schedules in Adult Patients With Advanced Hematological Malignancies

Novartis Pharmaceuticals·interventional·Posted Feb 22, 2008·Updated Jan 5, 2021

In Brief

A Phase 2 clinical trial evaluating LBH589 for Lymphoma and 2 related conditions. Completed, enrolled 175 participants across 7 sites in 3 countries.

Detailed Summary

This study evaluated safety, tolerability, pharmacokinetics and preliminary anti-leukemic or anti-tumor activity of LBH589B in adult patients with advanced hematological malignancies

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Leukemia, Multiple Myeloma
CountriesAustralia, Germany, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 22, 2008
Enrollment StartMar 1, 2003
Primary CompletionDec 3, 2009
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 18.4 years ago

Interventions

LBH589drug